SLS at a glance
SELLAS Life Sciences Group, Inc. (SLS, SEC CIK 1390478) filed its latest 10-K annual report on March 19, 2026, a 10-Q quarterly report on August 11, 2026, an 8-K current report on August 11, 2026 and Form 4 insider filings as recently as June 18, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2023 (FY2023), SELLAS Life Sciences Group, Inc. (SLS) reported revenue of $0 and a net loss of $37.3 million. Diluted EPS was -$1.34.
- As of June 30, 2026, 23 institutional investment managers tracked by SignalX reported holding SELLAS Life Sciences Group, Inc. (SLS) shares worth $666.6 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2023
- $0
- 10-K XBRL
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 23 funds
- $666.6M · −1 vs prior quarter
- Latest 8-K
- Aug 11, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Quarterly revenue $0, unchanged from $0 YoY; no product sales
- Net loss $9.6M vs $6.6M YoY; operating loss $10.6M vs $6.9M
- Research and development $6.3M vs $3.9M; SLS009 costs $1.7M, GPS costs $1.1M
- Cash and equivalents $138.3M plus restricted cash $0.1M; operating cash use $16.4M vs $16.4M
- Outlook: cash sufficient for at least twelve months; R&D expenses expected to increase with GPS and SLS009 trials
Risk Factors
- No material risk-factor changes disclosed from the 2025 Annual Report
- Clinical-development risk carried forward through reliance on successful trials and regulatory approvals
- Financing risk carried forward from continued dependence on additional capital to fund operations
- Stock-price risk heightened by directors’ Rule 10b5-1 plans covering 45,000 shares
AI summary of the SLS 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 financial results for quarter ended June 30, 2026
- Corporate update furnished in Exhibit 99.1
Item EX-99.1: Item EX-99.1
- Q2 2026 net loss $9.6M, or $0.05 per share, versus $6.6M and $0.07 in Q2 2025
- Cash $138.3M at June 30, 2026, supporting GPS REGAL analysis and SLS009 clinical development
Item 2.02: Results of Operations and Financial Condition
- Preliminary unaudited cash and cash equivalents of $138.3 million as of June 30, 2026
- Six-month financial closing procedures remain incomplete, creating potential for material adjustment
Item 8.01: Other Events
- Arbitration claims against 3D Medicines dismissed on July 24, 2026
- SLS responsible for approximately $1.0 million of 3D Medicines’ legal fees and costs
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Enhanced retention protections for CEO, CFO and Chief Development Officer through amended severance and change-of-control agreements
- CFO and Chief Development Officer receive nine months’ salary, pro rata target bonus and up to nine months’ COBRA outside change of control
AI summaries of SLS 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for SLS
Don't miss the next SLS filing
- Alerts as it files. A push when SLS files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut SLS, by share count.
- Ask anything. An AI agent that reads every SLS filing and answers with sources.
SLS alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Stergiou Angelos M. | A | Jun 16, 2026 | 1,065,000 | - |
| Stergiou Angelos M. | A | Jun 16, 2026 | 1,065,000 | - |
| Kalin Katherine Bach | A | Jan 7, 2026 | 50,000 | - |
| Wasman Jane | A | Jan 7, 2026 | 50,000 | - |
| VAN NOSTRAND ROBERT L | A | Jan 7, 2026 | 50,000 | - |
| CICIC DRAGAN | A | Jan 7, 2026 | 300,000 | - |
| Varian John | A | Jan 7, 2026 | 50,000 | - |
| Burns John Thomas | A | Jan 7, 2026 | 300,000 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|
| Profitability | ||||
| Revenue | $0 | - | - | |
| Operating Income | -$37.9M | -$31.5M | -$28.3M | |
| Net Income | -$37.3M | -$30.9M | -$26.9M | |
| Balance Sheet | ||||
| Total Assets | $6.2M | $19.4M | $78.3M | |
| Equity | -$8.0M | $9.5M | $70.9M | |
| ROE | 468.2% | -326.3% | -37.9% | |
| Per Share | ||||
| EPS | $-1.34 | $-0.50 | $-0.25 | |
| Cash Flow | ||||
| Operating CF | -$31.4M | -$35.4M | -$28.4M | |
Source: XBRL data in SELLAS Life Sciences Group, Inc. (SLS)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate SLS share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 23 | $666.6M |
| Q1 2026 | 24 | $151.6M |
| Q4 2025 | 18 | $97.2M |
| Q3 2025 | 19 | $28.6M |
| Q2 2025 | 17 | $37.2M |
| Q1 2025 | 9 | $4.4M |
| Q4 2024 | 5 | $3.5M |
| Q3 2024 | 6 | $895,000 |
- State Street Corp+4.60M (+55%)
- BlackRock+2.87M (+24%)
- Vanguard Capital Management LLC+700.2K (+9%)
- Vanguard Portfolio Management LLC+698.3K (+48%)
- Northern Trust+343.9K (+27%)
- Invesco Ltd−322.7K (-46%)
- Morgan Stanley−100.0K (-7%)
- Renaissance Technologies LLC+310.4K
- Franklin Resources+119.2K
- Mangrove Partners+34.1K
- Two Sigma Investments−403.2K
- Millennium Management−159.5K
- Citadel Advisors LLC−64.6K
- Marex Group plc−10.8K
Source: 13F-HR filings on SEC EDGAR (aggregated from 121 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
SLS filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Aug 11, 2026 | - | Analysis | - |
| 10-Q | Aug 11, 2026 | Jun 30, 2026 | Analysis | |
| SC 13G | Aug 7, 2026 | - | - | |
| SC 13G | Jul 31, 2026 | - | - | |
| 8-K | Jul 27, 2026 | - | Analysis | - |
| 8-K | Jun 25, 2026 | - | Analysis | - |
| 4 | Jun 18, 2026 | - | - | - |
| 8-K | Jun 18, 2026 | - | Analysis | - |
| 8-K | Jun 2, 2026 | - | Analysis | |
| 10-Q | May 12, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 12, 2026 | - | Analysis | |
| 10-K | Mar 19, 2026 | Dec 31, 2025 | - | |
| 8-K | Mar 19, 2026 | - | Analysis | - |
| 8-K | Mar 11, 2026 | - | Analysis | - |
| 4 | Jan 9, 2026 | - | - | |
| 4 | Jan 9, 2026 | - | - | |
| 4 | Jan 9, 2026 | - | - | |
| 4 | Jan 9, 2026 | - | - | |
| 4 | Jan 9, 2026 | - | - | |
| 4 | Jan 9, 2026 | - | - | |
| 4 | Jan 9, 2026 | - | - | |
| 8-K | Jan 8, 2026 | - | - | |
| 4 | Dec 5, 2025 | - | - | |
| 4 | Dec 5, 2025 | - | - | |
| 4 | Dec 5, 2025 | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
SLS SEC filings: frequently asked questions
Which institutions hold SLS stock?
As of June 30, 2026, the largest SELLAS Life Sciences Group, Inc. (SLS) holders among the 13F filers tracked by SignalX were BlackRock ($222.4 million), State Street Corp ($191.8 million), Vanguard Capital Management LLC ($121.4 million), Vanguard Portfolio Management LLC ($31.9 million), Northern Trust ($23.9 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was SLS's revenue in fiscal year 2023?
For the fiscal year ended December 31, 2023 (FY2023), SELLAS Life Sciences Group, Inc. (SLS) reported revenue of $0 and a net loss of $37.3 million. Diluted EPS was -$1.34. The figures come from the XBRL data in the 10-K.
What did SLS report in its latest 8-K?
SELLAS Life Sciences Group, Inc. (SLS) filed an 8-K on August 11, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q2 2026 financial results for quarter ended June 30, 2026.
What are the latest SLS SEC filings?
SELLAS Life Sciences Group, Inc. (SLS) filed its latest 10-K annual report on March 19, 2026, a 10-Q quarterly report on August 11, 2026, an 8-K current report on August 11, 2026 and a Form 4 insider filing on June 18, 2026.
What is SLS's SEC CIK number?
SELLAS Life Sciences Group, Inc. (SLS)'s SEC Central Index Key (CIK) is 1390478. EDGAR lists every SLS filing under that number.
Ask anything about SLS
The research agent reads SLS's filings, financials, insider trades and 13F holders, then answers with sources.